La inhibición de la lactancia materna en el puerperio inmediato se realiza habitualmente con cabergolina, 1mgr en dosis única.
La carbegolina es un agonista dopaminérgico selectivo de acción prolongada. Inhibe la síntesis de prolactina por estimulación directa de receptores D2 de los lactotrofos pituitarios de modo dosis dependiente, siendo la mayoría de sus reacciones adversas leves.
Los efectos secundarios graves, y poco frecuentes, se asocian principalmente con trastornos pleuropulmonares, cardiacos y valvulopatías. Estas raras complicaciones se asocian más a pacientes con lesiones leves fibróticas de válvulas cardíacas y en tratamientos a largo plazo como en el caso de tratamiento enfermedad de Parkinson y de disfunciones hiperprolactinemicas.
In order to inhibit lactation in women during the puerperal phase, a single, oral dose of cabergoline is administered.
The cabergoline is a long-acting selective dopamine agonist. It inhibits the prolactin synthesis by direct stimulation of D2 receptor in pituitary lactotrophs in a dose dependent. Most of its adverse reactions are slight.
Most commonly, this treatment causes only mild side effects, however, cabergoline can also cause severe side effects including valvulopathy and cardiopulmonary fibrotic reactions. These severe adverse reactions are predominantly observed in patients which are given high daily doses of the drug over a prolonged period of time, as is usual in the treatment of illnesses such as hyperprolactinaemia or Parkinson´s disease.
We present a case of pericardial effusion and bilateral pleural effusion in a patient during the puerperium, after being treated with two single low-dose cabergoline tablets to inhibit lactation.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados